SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension - 2Looking for under-the-radar adventures? Try Norway's Vesterålen
- 3Ancient meditation practices find new life in modern religious communities across America
- 4Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- 5Mom warns of Christmas gift hazard as daughter recovers in hospital
- 4 Famous Attractions at Disneyland
- Explainer-What will change with the US reclassification of marijuana?
- Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
- A Manual for Well known Western television Series
- The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- General Atlantic says ‘biggest mistake’ would be pulling back on Gulf deals
- Syria rejects forced deportations from Germany amid migration debate
- Newly Identified ‘Lucy’s Hunter’ Was a 15-Foot Crocodile Lurking in Ancient Ethiopia
